Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine Pre-conditioning in High Risk AML and MDS
NCT01422603Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Feb 2011
- Primary completion
- May 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of clofarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Treatment Related Mortality at 1 year. Started Feb 2011; status: completed.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01422603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01422603.